Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-01-19
1998-03-03
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 49, 514 68, 514218, 514533, A61K 3170, A61K 3155, C07D24104, A01N 4362
Patent
active
057234493
ABSTRACT:
Methods and pharmaceutical compositions effective to increase intracellular and plasma uridine concentrations are disclosed. Certain compositions and methods of using such compositions have been found to be effective to inhibit uridine secretion in a subject, thus increasing uridine concentration. Treatments that increase uridine concentrations are useful to combat many treatments and can also be effective in protecting or rescuing uninfected and normal cells that are subject to toxic side effects induced by the administration of certain chemotherapeutic compounds.
REFERENCES:
patent: 4613603 (1986-09-01), Biziere et al.
patent: 4613604 (1986-09-01), Chua et al.
patent: 4874602 (1989-10-01), Calabresi et al.
patent: 4950466 (1990-08-01), Calabresi et al.
patent: 5064946 (1991-11-01), Shover et al.
patent: 5077280 (1991-12-01), Sommadossi et al.
patent: 5141943 (1992-08-01), Naguib et al.
patent: 5567689 (1996-10-01), Sommadossi et al.
"Tissue-specific Enhancement of Uridine Utilization and 5-Fluorouracil Therapy in Mice by Benzylacyclouridine," Darnowski et al., Cancer Res. 45:5364-5368 (Nov. 1985).
"Clinical and Pharmacological Study of Orally Administered Uridine," van Groeningen et al., J. Natl. Cancer. Inst. 43*6):437-441 (Mar. 20, 1991).
"High-Dose 5-Fluoroucacil with Delayed Uridine Rescue in Mice," Martin et al., Cancer Res. 42:3964-3970 (Oct. 1982).
"Enhancement of Fluorouracil Therapy By the Manipulation of Tissue Uridine Pools," Darnowski et al., Pharmac. Ther. 41:381-392 (1989).
"Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzyllacyclouridine," Martin et al., Cancer Chemother. Pharmacol. 24:9-14(1989).
"Effect of uridine supply on glycogen resynthesis after ischemia in the isolated perfused rat heart," J. Aussedat, Cardiovasc. Res. 17:145-151 (1983).
"Anticonvulsant Activities of .increment.-8 and .increment.-9 Tetrahydrocan-nabinol and Uridine," Dwivedi et al., Toxicol. and App. Pharmacol. 31:452-458 (1975).
"Effects of Nucleosides on Acute Left Ventricular Failure in the Isolated Dog Heart," Buckley et al., Circulation Res. VII:847-857 (Nov. 1959).
"Influence of Certain Nucleosides on Glucose Utilization in Man," Elrick et al., Metabolism X(1): 46-55 (Jan. 1962).
"The Relationship Between Uracil Nucleotide Concentrations And Glycogen Synthesis in Hepatocytes From Fed And Fasted Rats," Songu et al., Metabolism 30(2):119-122 (Feb. 1981).
"Dilazep: an inhibitor of adenosine uptake with intrinsic calcium antagonistic properties," Tonini et al., J. Pharm. Pharmacol. 35:434-439 (1983).
"First Report of Management and Outcome of Pregnancies Associated with Hereditary Orotic Aciduria," Bensen et al., Am. J. Med. Gen. 41:426-431 (1991).
"Uridine Incorporation in Normal and Ischaemic Perfused Rat Heart," Aussedat et al., Mol. Phys. 6:247-256 (1984).
"Benzyllacyclouridine Reverses Azidothymidine-Induced Marrow Suppression Without Impairment of Anti-Human Immunodeficiency Virus Activity," Calabresi et al., Blood 76(11):2210-2215 (Dec. 1, 1990).
"Interaction of Uridine with Gaba Binding Sites in Cerebellar Membranes of the Rat," Guarneri et al., Neurochem. Res. 8(12):1537-1545 (1983).
"Phase I and Pharmacokinetic Studies of High-Dose Uridine Intended for Rescue from 5-Fluorouracil Toxicity," Leyva et al., Cancer Res. 44:5928-5933 (Dec. 1984).
"Enhancement of the Antitumor Activity of 5-Fluorouracil by Uridine Rescue," Klubes et al., Biochem. Pharmacol. 26:1585-1591 (1977).
"Interaction Between Uridine and GABA-Mediated Inhibitory Transmission: Studies In Vivo and In Vitro," Guarneri et al., Epilepsia 26(6):666-671 (1985).
"Cytidine and Uridine Requirement of the Brain," Geiger et al., J. Neurochem. 1:93-100 (1956).
"Effects of Uridine and Inosine on Glucose Metabolism in Skeletal Muscle and Activated Lipolysis in Adipose Tissue," Kypson et al., J. Pharmacol. and Exptl. Therapeutics 199(3):565-574 (1976).
"Effect of Cytidine and Uridine on Regeneration of the Liver in Rats Poisoned with Carbon Tetra-chloride," Bushma et al., Bull. Exptl. Bio. Med. 88:1480-1483 (1980).
"Effects of Uridine on the Performance and the Metabolism of Oxygenated and Hypoxic Rabbit Hearts," Kypson et al. J. Mol. Cell. Cardiol. 10:545-565 (1978).
"Anticonvulsant Effects of Uridine: Comparative Analysis of Metrazol and Penicillin Induced Foci," C.A. Roberts, Brain Res. 55:291-308 (1973).
"Metabolic Effects of Inosine and Uridine in Rabbit Hearts and Rat Skeletal Muscles," Kypson, et al., Biochem. Pharmacol. 26:1585-1591 (1977).
Jurovcik et al. Nucl. Acids Res. 3(8):2143-2154 (1976).
el Kouni Mahmoud H.
Sommadossi Jean-Pierre
Kunz Gary L.
The UAB Research Foundation
LandOfFree
Methods and compositions for inhibiting uridine secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting uridine secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting uridine secretion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2247754